The liver is an endocrine organ because hepatocytes produce a number of biologically active regulators of systemic metabolism and energy balance – hepatokines, which include orosomucoids (seromucoids). According literuture data, orosomucoids reduce the production of activated oxygen forms, protect adipose tissue, regulate immune processes, act as cardioprotectors, and drug carriers. Orosomucoids production is associated with the development of fatty hepatosis too but pathogrenetic role of orosomucoids in liver steatosis needs more investigations. The objective: to evaluate the effects of orosomucoids on systemic metabolism in patients with coronary artery disease with comorbid liver steatosis. Materials and methods. In 104 patients with coronary artery disease, unstable angina the content of orosomucoids was additionally determined by the unified orcin’s method (normal value 0,13–0,23 units). Patients were investigated according modern quidelines and Helsinki declaration of human rights. According liver steatosis presentce patients were divided into two statistically equal groups with comorbid liver steatosis (n=87; 83,65%) and intact liver (n=17; 16,35%). The results were calculated statistically with p<0.05 level. Results. Patients with and without hepatic steatosis had identically elevated orosomucoids levels (0,38±0,02 vs 0,40±0,05 units; p>0.05), but their correlations were different. The level of orosomucoids correlated directly with the duration of inpatient treatment, heart rate, acute-phase indicators of inflammation, fasting blood glucose and prothrombin time, and was conversely associated with total cholesterol and low-density lipoproteins, prothrombin index (all p<0.05). Conclusions. Orosomucoid hepatokines are key regulators of lipogenesis, under conditions of liver steatosis in patients with coronary artery disease, unstable angina, their growth correlates with activation of cellular and serum markers of inflammation, reduction of serum atherogenicity, glucose intolerance, and hypocoagulation.